The insulin-like growth factor system as a target in breast cancer

Breast Cancer Research and Treatment

Volumn 32, Issue 1, 1994, Pages 85-95

  Yee, Douglas ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

autocrine growth factors; IGF binding proteins; IGF receptors; insulin like growth factors; MCF 7 breast cancer cells; targeted therapy

Indexed keywords

CELL SURFACE RECEPTOR; ESTROGEN RECEPTOR; FENRETINIDE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA;

BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMAL; BREAST NEOPLASMS; CARRIER PROTEINS; CELL DIVISION; HUMAN; INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN 1; RECEPTORS, SOMATOMEDIN; SOMATOMEDINS; TUMOR CELLS, CULTURED;

EID: 0027942034     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/BF00666209     Document Type: Article

References (69)

1. IGF binding proteins and their functions
2. The IGF-II receptor system — a Gprotein-linked mechanism
3. Molecular dynamics of insulin/IGF-I receptor transmembrane signaling
4. Phylogeny of the insulin-like growth factors (IGFs) and receptors — a molecular approach
5. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations
6. Laron dwarfism and mutations of the growth hormone receptor gene
7. Mice carrying null mutations of the genes encoding insulin-like growth factor-I (Igf-1) and type-1 IGF receptor (Igflr)
8. Role of insulin-like growth factors in embryonic and postnatal growth
9. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define hormonal specificity
10. Expression and characterization of a functional human insulin-like growth factor I receptor
11. Inhibition of the mitogenic effects of plasma by a monoclonal antibody to somatomedin C
12. Dual control of cell growth by somatomedins and platelet-derived growth factor
13. Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors
14. Insulin-like growth factor II receptor as a multifunctional binding protein
15. Structure of the receptor for insulin-like growth factor II: the puzzle amplified
16. Possible direct linkage of insulin-like growth factor II receptor with guanine nucleotide-binding protein
17. Distinctive regulation of the functional linkage between the human cation-independent mannose 6-phosphate receptor and GTP-binding proteins by insulin-like growth factor II and mannose 6-phosphate
18. Intramolecular subunit interactions between insulin and insulin-Like growth factor-1 αβ half-receptors induced by ligand and Mn/MgATP binding
19. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity
20. Insulin-like growth factor I receptor β-subunit heterogeneity, evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers
21. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5, and -6)
22. Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects of affinity for IGF-I
23. Insulin-like growth factor binding protein-1 stimulates cell migration and binds α5β1 integrin by means of its arg-gly-asp sequence
24. Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T-47D) in culture
25. Insulin-like growth factor II mRNA expression in human breast cancer
26. Insulin-like growth factor receptor expression and function in human breast cancer
27. Insulin-like growth factor II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor
28. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor
29. Interactions of cathepsin-D and insulin-like growth factor II (IGF-II) on the IGF-II/mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II
30. Analysis of IGF-I gene expression in malignancy, evidence for a paracrine role in human breast cancer
31. Characterization and hormonal regulation of radioimmunoassayable IGF-I (insulin-like growth factor I) like activity and IGF-binding proteins secreted by human breast cancer cells
32. Autocrine production of insulin-like growth factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells
33. Insulin-like growth factor-II expression in MCF-7 cells induces phenotypic changes associated with malignant progression
34. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells
35. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice
36. Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor-II (IGF-II)
37. Expression of IGF-I and IGF-II mRNA in breast tissue
38. Insulin-like growth factor-1 receptors in human breast tumours — localisation and quantification by histo-autoradiographic analysis
39. Prognostic significance of insulin-like growth factor I receptors in human breast cancer
40. Prognostic value of receptors for insulin-like growth factor I, somatostatin, and epidermal growth factor in human breast cancer
41. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer
42. Progestins induce down-regulation of insulin-like growth factor-I receptors in human breast cancer cells: potential autocrine role for IGF-II
43. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer
44. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients
45. Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy
46. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor-I levels in breast cancer patients
47. The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxy-androstenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer
48. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status
49. Identification of insulin-like growth factor binding proteins in breast cancer cells
50. Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action
51. Retinoid modulation of insulin-like growth factor-binding proteins and inhibition of breast carcinoma proliferation
52. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells — cell surface binding and growth inhibition
53. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells
54. Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status
55. IGFBP-3 gene expression and estrogen receptor status in human breast carcinoma
56. Blockade of the epidermal growth factor receptor inhibits transforming growth factor-α induced but not estrogen induced growth of hormone dependent human breast cancer
57. TGF-alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice
58. Purification of a 31,000-dalton insulin-like growth factor binding protein from human amniotic fluid, isolation of two forms with different biological actions
59. An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I
60. Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells
61. Expression of insulin-like growth factor-I inhibits IGF-I mediated growth in MCF-7
62. Secretion and biological actions of insulin-like growth factor binding proteins in two human tumor-derived cell lines in vitro
63. The insulin-like growth factor binding protein BP-25 is expressed by human breast cancer cells
64. Determination of the pharmacokinetic profiles of insulin-like growth factor binding protein-1 and protein-2 in rats
65. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor-I
66. Treatment and prevention of rat glioblastoma by immunogenic c6 cells expressing antisense insulin-like growth factor-I RNA
67. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
68. Sporadic amplification of the insulin-like growth factor I receptor gene in human breast tumors
69. The growth-stimulatory effect of simian virus-40 T-antigen requires the interaction of insulin-like growth factor-1 with its receptor